Premarket Stock Movers — September 9, 2026: Why ODD, SUNE, YMAT & IRD Are Surging

ODD — Oddity Tech Ltd (+33.0%)

Oddity Tech is surging +33.0% to $17.30 in premarket trading this morning on volume of 1,759,210 shares — more than double its 20-day average of 819,471. That kind of premarket volume on more than twice normal turnover signals a significant catalyst or a sharp wave of short-covering flooding in before the open.

Why it's moving: No headline or filing-based catalyst is on file for this move. The company has filed multiple Form 144s (insider sale notices) over the past two weeks — a routine disclosure when insiders plan to sell restricted shares, generally neutral in isolation — but nothing in the filing record explains a +33% surge. With no confirmed news, this looks like a momentum- or sentiment-driven spike, potentially amplified by short-covering. The catalyst is unclear, and traders should treat this as unconfirmed.

The short-squeeze setup is the most notable technical feature heading into this morning. ODD carries a squeeze score of 86/100 on the StockSetups scan — one of the highest readings in the system. Short interest stands at 6,583,805 shares with 8.7 days to cover, meaning shorts would need 8.7 days of average volume to fully exit their positions. When a stock with that much short interest catches an unexpected move higher, those short-sellers can be forced to buy back shares to limit losses — a feedback loop that amplifies price gains far beyond what the underlying news would normally justify. That dynamic appears to be at work here.

On the chart coming into this morning, ODD was in a technically weak posture: a bearish moving-average stack, an RSI of just 42 (not oversold, but soft), an ADX of 16 (weak trend), and a relative strength rating of only 7 — sitting 79.6% below its 52-week high. Conviction was 44/100, grade D. This was not a stock in an uptrend; it was a beaten-down name with a heavy short load. That combination — depressed price, high short interest, high days to cover — is precisely the profile that can produce violent, short-lived squeezes. The smart-money score is 25/100, and the largest disclosed stake is 22.4%, so institutional enthusiasm has been muted.

Risk note: A +33% premarket move in a stock with no confirmed catalyst, sitting near multi-year lows, with a bearish trend structure is a high-risk situation. Squeezes can reverse as quickly as they ignite once short-covering exhausts itself. This is not a signal of a fundamental turnaround.

SUNE — SUNation Energy, Inc. (+29.0%)

SUNation Energy is surging +29.0% to $3.07 premarket on extraordinary volume: 11,794,109 shares versus a 20-day average of just 158,392. That is roughly 74 times normal volume before the open — the clearest sign in today's mover list that a specific, major catalyst has hit this name.

Why it's moving: The catalyst is a headline from Yahoo Finance dated September 8: "Suniva Completes $835 Million Capital Raise to Build Second Major U.S. Solar Cell Manufacturing Facility and More Than Quadruple Capacity to 5.5 GW." While Suniva and SUNation Energy are distinct entities, two Form 425 filings (the SEC form used for merger-related communications) were filed on September 8, alongside an 8-K disclosing an agreement and a reg FD event. This combination strongly suggests SUNE is involved in or closely associated with a merger or deal announcement connected to the Suniva capital raise news. Traders appear to be bidding SUNE aggressively on the deal-related filings.

The technical picture coming into today was mixed but improving. SUNE carried an RSI of 51, an ADX of 30 (a meaningful trend reading), and a mixed moving-average stack — neither cleanly bullish nor bearish. Notably, its RS rating of 95 and a conviction score of 62/100 (grade B) suggest the stock had already been outperforming the broader market on a relative basis even before this morning's spike. It sits 59.5% below its 52-week high, so there is a significant gap to recover, but the RS rating shows institutional or momentum money had been accumulating relative strength in recent weeks.

The short squeeze profile here is modest — a squeeze score of 20/100, short interest of just 169,682 shares, and only 1.2 days to cover. This move is not short-squeeze driven; it is news driven. The 100% free float means all shares are available to trade, and the surge is purely a reaction to the deal/capital-raise news. Adding to the bullish tone: the CEO Scott Maskin bought 554,712 shares ($982K) and CFO James Robert Brennan bought 123,254 shares ($218K) back in April, signaling management conviction in the company's future even before this announcement.

Risk note: Merger-related moves and deal announcements can see sharp reversals if deal terms disappoint or if traders who bought on the rumor sell on the confirmation. The 74× volume spike shows this is a crowded trade heading into the open.

YMAT — J-Star Holding Co., Ltd. (+26.9%)

J-Star Holding is trading up +26.9% to $1.84 in premarket action, with volume of 18,181,893 shares against a 20-day average of just 19,474. That is approximately 934 times normal volume — an almost incomprehensible surge that signals either a major catalyst or extreme speculative activity in a very thinly traded name.

Why it's moving: No headline or filing-based catalyst is on file for YMAT. With no confirmed news, the catalyst is unclear, and this move appears to be technically and momentum-driven in nature. What makes YMAT structurally explosive is its free float of just 1.7% — meaning only a tiny fraction of the company's shares are available for public trading at any given time. A low float (a small number of shares available to trade) acts like a pressure cooker: even a modest surge in buying interest has nowhere to go, sending prices sharply higher. With short-sale restriction (SSR) now active — a rule triggered when a stock drops 10%+ in a prior session that limits aggressive short-selling — downward pressure from new short positions is also constrained this morning.

The conviction score heading into today was a strong 82/100, grade A, with an RSI of 34 (near oversold territory) and an ADX of 31 (meaningful directional momentum). The stock was 40.8% below its 52-week high, but the mixed MA stack and strong RS rating of 94 suggest relative strength had been building. The short position is tiny (17,094 shares, 0.6 days to cover), so this is not a squeeze story — it is a float story. When a 1.7% float stock attracts 934× average volume, prices can move violently in either direction.

No smart-money data is on file for YMAT. At a $20.2M market cap, this is a micro-cap name where liquidity is extremely thin. These characteristics — micro-cap, near-zero float, no disclosed catalyst, SSR active — define the highest-risk category of premarket movers.

Risk note: Ultra-low-float stocks with no confirmed catalyst are among the most dangerous to chase. They can give back gains in minutes once momentum fades. Extreme caution is warranted.

IRD — Opus Genetics, Inc. (+24.7%)

Opus Genetics is up +24.7% to $5.41 in premarket trading on volume of 2,377,770 shares — about 1.8× its 20-day average of 1,300,030. For a healthcare name, that kind of volume on a clinical data readout is substantial and reflects broad market participation in a genuinely significant event.

Why it's moving: The catalyst is clear and confirmed. A Yahoo Finance headline dated this morning reads: "Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027." In plain terms, the company's gene therapy candidate OPGx-BEST1 produced positive early-stage trial results in its lowest-dose patient group, and Opus has had a productive meeting with the FDA that is clearing the runway toward a Phase 3 study as early as 2027. Positive Phase 1/2 data combined with FDA alignment is a meaningful derisking event for a clinical-stage biotech — it reduces (though never eliminates) the risk that a drug will fail before reaching late-stage trials.

The technical setup coming into this morning was already one of the stronger setups among today's movers. IRD had a conviction score of 84/100, grade A, a bullish moving-average stack, an RSI of 59 (healthy, not overbought), and an RS rating of 94. The stock sits 24.5% below its 52-week high — a much shallower drawdown than the other movers today — suggesting it was already recovering. The bearish belt hold candlestick flagged on the prior daily chart is worth watching; this pattern can signal that buyers are stepping in after a pullback, though confirmation is needed.

The short squeeze dimension adds another layer to the story. IRD's squeeze score is 78/100, with short interest of 11,248,349 shares and an imposing 15.3 days to cover — the highest days-to-cover reading among today's movers. "Days to cover" measures how many days of average volume it would take for all short-sellers to buy back their positions; at 15.3 days, shorts are heavily committed and deeply exposed to positive news catalysts. A data readout this strong is precisely the trigger that can force short-sellers to cover aggressively, amplifying the stock's move well beyond what the news alone might produce.

Risk note: Biotech clinical data moves are notoriously volatile. Even positive early-stage data can be met with profit-taking once the initial enthusiasm fades. Phase 1/2 results in a low-dose cohort do not guarantee Phase 3 success. The 15.3 days-to-cover figure means short-sellers may continue to feel pain, but also that some short-covering could be exhausting itself as the stock rises. See yesterday's top movers recap for more context on the market's recent momentum.

The bottom line

This morning's premarket movers span the full spectrum of catalyst types: a high-squeeze, no-news momentum spike (ODD), a deal-driven solar energy surge on extraordinary volume (SUNE), a micro-cap ultra-low-float explosion with no confirmed news (YMAT), and a genuine clinical data catalyst with a heavy short load behind it (IRD). Each tells a different story, but they share one truth — stocks that move 25–33% before the open are in high-volatility territory where risk management is everything.

Chasing extended premarket gains is one of the fastest ways to take a large loss. By the time most retail traders see these moves, institutional desks and algorithmic traders have already reacted. Squeezes reverse. Merger speculation fizzles. Thin-float pops collapse. Clinical data that looks transformative in the premarket can give back half its gains by midday. None of the above constitutes a buy recommendation — they are observations about what is moving and why.

StockSetups scans the full ~12,300-stock US universe every premarket morning, flagging the biggest movers, detecting chart patterns confirmed by candlesticks, and computing conviction, squeeze, and smart-money scores so you can assess each opportunity with real data — not guesswork. Always do your own research and size your risk accordingly.